Results 91 to 100 of about 18,506 (177)
Optimization of high-dose busulfan dosing in bone marrow transplant patients
Objective. To review the pharmacokinetics profile of (HD-BU) high-dose busulfan, review published phar macodynamic relationships of high-dose busulfan and discuss clinical considerations of monitoring patients receiving high-dose busulfan. Data Sources.
Cheryl Tate, James S. Partyka
core +1 more source
ABSTRACT We describe a rare case of suspected delayed‐onset TA‐TMA with ocular and neurological involvement following allo‐HSCT. The condition was refractory to standard therapies; neurological improvement was temporally associated with ruxolitinib initiation, suggesting a possible GVHD overlap.
Lise‐Marie Pillet +13 more
wiley +1 more source
ABSTRACT Introduction The presentation of chronic myeloid leukemia (CML) in the blast phase as early T‐cell precursor acute lymphoblastic leukemia (ETP‐ALL) is very rare. As previously reported, in contrast to B‐ALL, the prognosis is poor. Case Presentation We encountered a patient with blast phase CML presenting as ETP‐ALL.
Takafumi Tsushima +10 more
wiley +1 more source
Background The aim of this study was to compare the long-term safety and efficacy of oral busulfan 12 mg/kg plus melphalan 140 mg/m2 and melphalan 200 mg/m2 as conditioning regimens for autologous stem cell transplantation in newly diagnosed patients ...
Juan José Lahuerta +19 more
doaj +1 more source
ABSTRACT Umbilical cord blood transplantation is a viable source of stem cells due to accessibility and low incidence of chronic graft‐versus‐host disease despite human‐leukocyte‐antigen mismatching. Disadvantages of low stem cell dose in larger recipients include delayed immune reconstitution, graft rejection, and mortality.
Rachel E. Granberg +4 more
wiley +1 more source
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo +2 more
wiley +1 more source
Human CD133 + stem cells were injected into the bone marrow cavity of NOG (NOD Shi-SCID IL2Rγc null ) mice with or without preconditioning of busulfan in order to assess the efficiency of human CD133 + cells engraftment.
Xiaofang Guo +6 more
doaj +1 more source
ABSTRACT Background Acute kidney injury (AKI) is a frequent and clinically relevant complication in allogeneic hematopoietic cell transplantation (HCT) recipients, particularly during the early post‐HCT period. Although AKI has been extensively reported in long‐term follow‐up studies, data focusing on the initial hospitalization phase remain limited ...
Luiz Carlos da Costa‐Junior +10 more
wiley +1 more source
ARTICLE HIGLIGHTS Busulfan can damage the liver by triggering oxidative stress Physalis angulata leaves show natural liver protective effects Extract reduced oxidative damage in liver tissue Liver structure improved after extract treatment Early ...
Elsi Rahmadhani +7 more
doaj +1 more source

